{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:02:19Z","timestamp":1790996539289,"version":"4.1.0"},"reference-count":166,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is one of the most common neurodegenerative disorders, characterized by an initial and progressive loss of dopaminergic neurons of the substantia nigra pars compacta via a potentially substantial contribution from protein aggregates, the Lewy bodies, mainly composed of \u03b1-Synuclein among other factors. Distinguishing symptoms of PD are bradykinesia, muscular rigidity, unstable posture and gait, hypokinetic movement disorder and resting tremor. Currently, there is no cure for PD, and palliative treatments, such as Levodopa administration, are directed to relieve the motor symptoms but induce severe side effects over time. Therefore, there is an urgency for discovering new drugs in order to design more effective therapeutic approaches. The evidence of epigenetic alterations, such as the dysregulation of different miRNAs that may stimulate many aspects of PD pathogenesis, opened a new scenario in the research for a successful treatment. Along this line, a promising strategy for PD treatment comes from the potential exploitation of modified exosomes, which can be loaded with bioactive molecules, such as therapeutic compounds and RNAs, and can allow their delivery to the appropriate location in the brain, overcoming the blood\u2013brain barrier. In this regard, the transfer of miRNAs within Mesenchymal stem cell (MSC)-derived exosomes has yet to demonstrate successful results both in vitro and in vivo. This review, besides providing a systematic overview of both the genetic and epigenetic basis of the disease, aims to explore the exosomes\/miRNAs network and its clinical potential for PD treatment.<\/jats:p>","DOI":"10.3390\/ijms24119547","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T04:41:49Z","timestamp":1685508109000},"page":"9547","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Parkinson\u2019s Disease: From Genetics and Epigenetics to Treatment, a miRNA-Based Strategy"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-8692","authenticated-orcid":false,"given":"Elena","family":"Paccosi","sequence":"first","affiliation":[{"name":"Unit of Molecular Genetics of Aging, Department of Ecology and Biology (DEB), University of Tuscia, 01100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2715-9113","authenticated-orcid":false,"given":"Luca","family":"Proietti-De-Santis","sequence":"additional","affiliation":[{"name":"Unit of Molecular Genetics of Aging, Department of Ecology and Biology (DEB), University of Tuscia, 01100 Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"ref_1","unstructured":"Parkinson, J. (1817). An Essay on the Shaking Palsy, Whittingham & Rowland."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"a0088622011","DOI":"10.1101\/cshperspect.a008862","article-title":"The history of parkinson\u2019s disease: Early clinical descriptions and neurological therapies","volume":"1","author":"Goetz","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"ref_4","first-page":"61","article-title":"The Differential Diagnosis and Treatment of Atypical Parkinsonism","volume":"113","author":"Levin","year":"2016","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3390\/biom5031467","article-title":"Is cell death primary or secondary in the pathophysiology of idiopathic Parkinson\u2019s disease?","volume":"5","year":"2015","journal-title":"Biomolecules"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2012.06.025","article-title":"Gene-environment interactions in Parkinson\u2019s disease: Specific evidence in humans and mammalian models","volume":"57","author":"Cannon","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2004.6.3\/galexander","article-title":"Biology of Parkinson\u2019s disease: Pathogenesis and pathophysiology of a multisystem neurodegenerative disorder","volume":"6","author":"Alexander","year":"2004","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.neuro.28.061604.135718","article-title":"Molecular pathophysiology of Parkinson\u2019s disease","volume":"28","author":"Moore","year":"2005","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of \u03b1-Synuclein: From structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4784268","DOI":"10.1155\/2018\/4784268","article-title":"Linking neuroinflammation and neurodegeneration in Parkinson\u2019s disease","volume":"2018","author":"Gelders","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.molmed.2012.03.002","article-title":"Beyond \u03b1-Synuclein transfer: Pathology propagation in Parkinson\u2019s disease","volume":"18","author":"Hansen","year":"2012","journal-title":"Trends Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fneur.2018.00295","article-title":"Alpha-synuclein: From early synaptic dysfunction to neurodegeneration","volume":"9","author":"Ghiglieri","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1034\/j.1399-0004.1998.5440401.x","article-title":"Genetics of Parkinson\u2019s disease","volume":"54","author":"Gasser","year":"1998","journal-title":"Clin. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.parkreldis.2004.03.006","article-title":"The neuromythology of Parkinson\u2019s Disease","volume":"10","author":"Calne","year":"2004","journal-title":"Park. Relat. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/mds.23948","article-title":"Parkinson\u2019s disease and alpha-synuclein","volume":"26","author":"Devine","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jmedgenet-2017-105047","article-title":"Genetics of Parkinson\u2019s disease and related disorders","volume":"55","author":"Zhang","year":"2018","journal-title":"J. Med. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha- synuclein in lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1523\/JNEUROSCI.0285-07.2007","article-title":"Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo","volume":"27","author":"Periquet","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease","volume":"18","author":"Kuhn","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.23894","article-title":"G51d alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome","volume":"73","author":"Lesage","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.4269","article-title":"\u03b1-Synuclein toxicity in neurodegeneration: Mechanism and therapeutic strategies","volume":"23","author":"Wong","year":"2017","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1212\/WNL.50.4.1136","article-title":"Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson\u2019s disease","volume":"50","author":"Chan","year":"1998","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ana.410430320","article-title":"Low frequency of alpha-synuclein mutations in familial Parkinson\u2019s disease","volume":"43","author":"Farrer","year":"1998","journal-title":"Ann. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/hmg\/7.4.751","article-title":"Sequencing of the \u03b1- synuclein gene in a large series of cases of familial Parkinson\u2019s disease fails to reveal any further mutations. The European Consortium on Genetic Susceptibility in Parkinson\u2019s Disease (GSPD)","volume":"7","author":"Vaughan","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1097\/00001756-199812010-00029","article-title":"Mutation screening in exons 3 and 4 of alpha-synuclein in sporadic Parkinson\u2019s and sporadic and familial dementia with Lewy bodies cases","volume":"9","author":"Curran","year":"1998","journal-title":"Neuroreport"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/mds.1198","article-title":"Analysis of the coding and the 5\u2019 flanking regions of the alpha-synuclein gene in patients with Parkinson\u2019s disease","volume":"16","author":"Pastor","year":"2001","journal-title":"Mov. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neulet.2004.05.100","article-title":"Alpha-synuclein missense and multiplication mutations in autosomal dominant Parkinson\u2019s disease","volume":"367","author":"Hope","year":"2004","journal-title":"Neurosci. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/mds.20504","article-title":"Alpha-synuclein and Parkinson\u2019s disease: Implications from the screening of more than 1900 patients","volume":"20","author":"Berg","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"Alpha-synuclein locus triplication causes Parkinson\u2019s disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"Alpha-synuclein locus duplication as a cause of familial Parkinson\u2019s disease","volume":"364","author":"Kachergus","year":"2004","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(04)17104-3","article-title":"Causal relation between alpha-synuclein gene duplication and familial Parkinson\u2019s disease","volume":"364","author":"Bonnet","year":"2004","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.20753","article-title":"Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson\u2019s disease","volume":"59","author":"Nishioka","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1086\/428655","article-title":"Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene","volume":"76","author":"Kowalak","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease","volume":"44","author":"Jain","year":"2004","journal-title":"Neuron"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.tins.2006.03.006","article-title":"LRRK2 in Parkinson\u2019s disease: Protein domains and functional insights","volume":"29","author":"Mata","year":"2006","journal-title":"Trends Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbadis.2008.09.015","article-title":"Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson\u2019s disease","volume":"1792","author":"Biskup","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-49969-7_1","article-title":"Kinase L-RR. (LRRK2) Genetics and Parkinson\u2019s disease","volume":"14","author":"Monfrini","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"16842","DOI":"10.1073\/pnas.0507360102","article-title":"Parkinson\u2019s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity","volume":"102","author":"West","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/01.wnl.0000240220.33950.0c","article-title":"Parkinsonism, LRRK2 G2019S, and tau neuropathology","volume":"67","author":"Rajput","year":"2006","journal-title":"Neurology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00401-006-0178-1","article-title":"LRRK2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions","volume":"113","author":"Ross","year":"2007","journal-title":"Acta Neuropathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers","volume":"41","author":"Schiffmann","year":"2004","journal-title":"J. Med. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajhg.2011.06.001","article-title":"VPS35 mutations in Parkinson disease","volume":"89","author":"Wider","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ajhg.2011.06.008","article-title":"A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease","volume":"89","author":"Zimprich","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/hmg\/ddt570","article-title":"DNAJC13 mutations in Parkinson disease","volume":"23","author":"Rajput","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1474-4422(14)70266-2","article-title":"CHCHD2 mutations in autosomal dominant late-onset Parkinson\u2019s disease: A genome- wide linkage and sequencing study","volume":"14","author":"Funayama","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"219.e1","DOI":"10.1016\/j.neurobiolaging.2016.10.007","article-title":"TMEM230 mutation analysis in Parkinson\u2019s disease in a Chinese population","volume":"49","author":"Yan","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/jmedgenet-2015-103616","article-title":"Evidence of mutations in RIC3 acetylcholine receptor chaperone as a novel cause of autosomal-dominant Parkinson\u2019s disease with non-motor phenotypes","volume":"53","author":"Sudhaman","year":"2016","journal-title":"J. Med. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJM200005253422103","article-title":"Association between early-onset Parkinson\u2019s disease and mutations in the parkin gene","volume":"342","author":"Bonifati","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1212\/01.WNL.0000049470.00180.07","article-title":"Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease","volume":"60","author":"Foroud","year":"2003","journal-title":"Neurology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"43628","DOI":"10.1074\/jbc.M308947200","article-title":"Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons","volume":"278","author":"Goldberg","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ana.1132","article-title":"Lewy bodies and parkinsonism in families with parkin mutations","volume":"50","author":"Farrer","year":"2001","journal-title":"Ann. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archneur.63.6.826","article-title":"Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: The GenePD study","volume":"63","author":"Sun","year":"2006","journal-title":"Arch. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ana.10179","article-title":"Role of parkin mutations in 111 community-based patients with early-onset parkinsonism","volume":"51","author":"Kann","year":"2002","journal-title":"Ann. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/jmg.39.7.489","article-title":"Linkage stratification and mutation analysis at the parkin locus identifies mutation positive Parkinson\u2019s disease families","volume":"39","author":"Nichols","year":"2002","journal-title":"J. Med. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/mds.20234","article-title":"Distribution, type, and origin of parkin mutations: Review and case studies","volume":"19","author":"Hedrich","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1212\/WNL.56.4.555","article-title":"Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations","volume":"56","author":"Lammens","year":"2001","journal-title":"Neurology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ana.10613","article-title":"How much phenotypic variation can be attributed to parkin genotype?","volume":"54","author":"Lohmann","year":"2003","journal-title":"Ann. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.parkreldis.2016.07.014","article-title":"Identification of a novel homozygous mutation Arg459Pro in SYNJ1 gene of an Indian family with autosomal recessive juvenile parkinsonism","volume":"31","author":"Kirola","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/mds.26876","article-title":"Novel compound heterozygous synaptojanin-1 mutation causes l-dopa-responsive dystonia-parkinsonism syndrome","volume":"32","author":"Rauschendorf","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s40478-020-01062-w","article-title":"PINK1\/PARKIN signalling in neurodegeneration and neuroinflammation","volume":"8","author":"Quinn","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/nature04779","article-title":"Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin","volume":"441","author":"Clark","year":"2006","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neures.2020.01.006","article-title":"The PINK1-Parkin axis: An Overview","volume":"159","author":"Tanaka","year":"2020","journal-title":"Neurosci. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9103","DOI":"10.1073\/pnas.0402959101","article-title":"The Parkinson\u2019s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization","volume":"101","author":"Wilson","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.embor.7400074","article-title":"DJ-1 has a role in antioxidative stress to prevent cell death","volume":"5","author":"Taira","year":"2004","journal-title":"EMBO Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10863-019-09798-4","article-title":"Role of DJ-1 in the mechanism of pathogenesis of Parkinson\u2019s disease","volume":"51","author":"Dolgacheva","year":"2019","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Shendelman, S., Jonason, A., Martinat, C., Leete, T., and Abeliovich, A. (2004). DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol., 2.","DOI":"10.1371\/journal.pbio.0020362"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jmb.2005.12.030","article-title":"The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein","volume":"356","author":"Zhou","year":"2006","journal-title":"J. Mol. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1077209","article-title":"Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism","volume":"299","author":"Bonifati","year":"2003","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ana.10663","article-title":"Early-onset Parkinson\u2019s disease caused by a compound heterozygous DJ-1 mutation","volume":"54","author":"Hague","year":"2003","journal-title":"Ann. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ana.10675","article-title":"The role of pathogenic DJ-1 mutations in Parkinson\u2019s disease","volume":"54","author":"Healy","year":"2003","journal-title":"Ann. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/humu.20089","article-title":"Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7)","volume":"24","author":"Hering","year":"2004","journal-title":"Hum. Mutat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bbrc.2006.05.011","article-title":"Increased level of DJ-1 in the cerebro- spinal fluids of sporadic Parkinson\u2019s disease","volume":"345","author":"Waragai","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/978-3-319-53889-1_19","article-title":"Epigenetics in Parkinson\u2019s Disease","volume":"978","author":"Pavlou","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.parkreldis.2013.12.002","article-title":"Methylation of alpha-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson\u2019s disease patients","volume":"20","author":"Tan","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1523\/JNEUROSCI.6119-09.2010","article-title":"Methylation regulates alpha-synuclein expression and is decreased in Parkinson\u2019s disease patients\u2019 brains","volume":"30","author":"Jowaed","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3334.e7","DOI":"10.1016\/j.neurobiolaging.2015.08.028","article-title":"DNA methylation levels of \u03b1-synuclein intron 1 in the aging brain","volume":"36","author":"Riedel","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1074\/jbc.C110.212589","article-title":"Alpha-synuclein sequesters Dnmt1 from the nucleus: A novel mechanism for epigenetic alterations in Lewy body diseases","volume":"286","author":"Desplats","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1074\/jbc.M115.675488","article-title":"Regulation of Histone Acetylation by Autophagy in Parkinson Disease","volume":"291","author":"Park","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"8465","DOI":"10.1021\/bi0341152","article-title":"Nuclear localization of alpha-synuclein and its interaction with histones","volume":"42","author":"Goers","year":"2003","journal-title":"Biochemistry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.nbd.2008.09.010","article-title":"Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability","volume":"32","author":"Pieper","year":"2008","journal-title":"Neurobiol Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.nbd.2011.12.046","article-title":"MicroRNAs in Parkinson\u2019s disease","volume":"46","author":"Mouradian","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuroscience.2014.04.039","article-title":"Downregulation of miR-124 in MPTP-treated mouse model of Parkinson\u2019s disease and MPP iodide-treated MN9D cells modulates the expression of the calpain\/cdk5 pathway proteins","volume":"272","author":"Kanagaraj","year":"2014","journal-title":"Neuroscience"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"13052","DOI":"10.1073\/pnas.0906277106","article-title":"Repression of alpha-synuclein expression and toxicity by microRNA-7","volume":"106","author":"Junn","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fncel.2014.00182","article-title":"miR-7 and miR-153 protect neurons against MPP(+)-induced cell death via upregulation of mTOR pathway","volume":"8","author":"Fragkouli","year":"2014","journal-title":"Front. Cell Neurosci."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Titze-de-Almeida, S.S., Soto-S\u00e1nchez, C., Fernandez, E., Koprich, J.B., Brotchie, J.M., and Titze-de-Almeida, R. (2020). The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson\u2019s Disease. Cells, 9.","DOI":"10.3390\/cells9040841"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"104515","DOI":"10.1016\/j.phrs.2019.104515","article-title":"miR-124 and Parkinson\u2019s disease: A biomarker with therapeutic potential","volume":"150","author":"Angelopoulou","year":"2019","journal-title":"Pharm. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.ymthe.2017.08.017","article-title":"Loss of MicroRNA-7 Regulation Leads to alpha-Synuclein Accumulation and Dopaminergic Neuronal Loss In Vivo","volume":"25","author":"McMillan","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"12726","DOI":"10.1074\/jbc.M109.086827","article-title":"Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153","volume":"285","author":"Doxakis","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/hmg\/ddr210","article-title":"MicroRNA profiling of Parkinson\u2019s disease brains identifies early downregulation of miR-34b\/c which modulate mitochondrial function","volume":"20","author":"Porta","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1140481","article-title":"A MicroRNA feedback circuit in midbrain dopamine neurons","volume":"317","author":"Kim","year":"2007","journal-title":"Science"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.molmed.2011.06.009","article-title":"NeurimmiRs: MicroRNAs in the neuroimmune interface","volume":"17","author":"Soreq","year":"2011","journal-title":"Trends Mol. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.brainres.2010.03.106","article-title":"MicroRNAs and deregulated gene expression networks in neurodegeneration","volume":"1338","author":"Sonntag","year":"2010","journal-title":"Brain Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"19291","DOI":"10.1073\/pnas.0709971104","article-title":"A biochemical approach to identifying microRNA targets","volume":"104","author":"Karginov","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.neuro.2017.04.007","article-title":"Environmental neurotoxicant manganese regulates exosome- mediated extracellular miRNAs in cell culture model of Parkinson\u2019s disease: Relevance to \u03b1-synuclein misfolding in metal neurotoxicity","volume":"64","author":"Harischandra","year":"2018","journal-title":"Neurotoxicology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fnagi.2017.00232","article-title":"MicroRNA- 4639 is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson\u2019s disease","volume":"9","author":"Chen","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"146331","DOI":"10.1016\/j.brainres.2019.146331","article-title":"Serum secreted miR-137-containing exosomes affects oxidative stress of neurons by regulating OXR1 in Parkinson\u2019s disease","volume":"1722","author":"Jiang","year":"2019","journal-title":"Brain Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2047-9158-1-10","article-title":"Drug therapy in patients with Parkinson\u2019s disease","volume":"1","year":"2012","journal-title":"Transl. Neurodegener."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson\u2019s Disease and Parkinsonism","volume":"132","author":"Hayes","year":"2019","journal-title":"Am. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Witwer","year":"2018","journal-title":"J. Extracell. Vesicles"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature08849","article-title":"Molecular mechanism of multivesicular body biogenesis by ESCRT complexes","volume":"464","author":"Wollert","year":"2010","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/mt.2011.164","article-title":"Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain","volume":"19","author":"Zhuang","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fphys.2012.00228","article-title":"Role of exosomes\/microvesicles in the nervous system and use in emerging therapies","volume":"3","author":"Lai","year":"2012","journal-title":"Front. Physiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/jcp.25739","article-title":"Diagnostic and therapeutic potential of exosomes in cancer: The beginning of a new tale?","volume":"232","author":"Mirzaei","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/jcb.26271","article-title":"Molecular aspects of diabetes mellitus: Resistin, microRNA, and exosome","volume":"119","author":"Esfandiary","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/iub.2211","article-title":"MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis","volume":"72","author":"Pourhanifeh","year":"2019","journal-title":"IUBMB Life"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jconrel.2014.07.049","article-title":"Extracellular vesicles as drug delivery systems: Lessons from the liposome field","volume":"195","author":"Fens","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","article-title":"Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: Current perspectives and future challenges","volume":"6","author":"Ha","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acn3.175","article-title":"Identification of distinct circulating exosomes in Parkinson\u2019s disease","volume":"2","author":"Tomlinson","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1182\/blood.V94.11.3791","article-title":"Activated platelets release two types of membrane vesicles: Microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules","volume":"94","author":"Heijnen","year":"1999","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nrm3335","article-title":"Intercellular communication: Diverse structures for exchange of genetic information","volume":"13","author":"Mittelbrunn","year":"2012","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.scr.2009.12.003","article-title":"Exosome secreted by MSC reduces myocardial ischemia\/reperfusion injury","volume":"4","author":"Lai","year":"2010","journal-title":"Stem Cell Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/pmic.201200373","article-title":"The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles","volume":"13","author":"Katsuda","year":"2013","journal-title":"Proteomics"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/STROKEAHA.110.601914","article-title":"Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II","volume":"42","author":"Savitz","year":"2011","journal-title":"Stroke"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/STROKEAHA.114.007803","article-title":"Stem Cell-Based Tissue Replacement After Stroke: Factual Necessity or Notorious Fiction?","volume":"46","author":"Janowski","year":"2015","journal-title":"Stroke"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fnagi.2018.00077","article-title":"Recent Advances: Decoding Alzheimer\u2019s Disease with Stem Cells","volume":"10","author":"Fang","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/stem.1409","article-title":"MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles","volume":"31","author":"Xin","year":"2013","journal-title":"Stem Cells"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fneur.2018.00931","article-title":"MicroRNA-21 Overexpression Promotes the Neuroprotective Efficacy of Mesenchymal Stem Cells for Treatment of Intracerebral Hemorrhage","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"10772","DOI":"10.1038\/s41598-020-67460-1","article-title":"Bone marrow-derived mesenchymal stem cells improve cognitive impairment in an Alzheimer\u2019s disease model by increasing the expression of microRNA-146a in hippocampus","volume":"10","author":"Nakano","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/glia.22558","article-title":"Schwann cell-derived exosomes enhance axonal regeneration in the peripheral nervous system","volume":"61","author":"Picou","year":"2013","journal-title":"Glia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jconrel.2018.08.035","article-title":"Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson\u2019s disease","volume":"287","author":"Qu","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2015.03.033","article-title":"Exosomes as drug delivery vehicles for Parkinson\u2019s disease therapy","volume":"207","author":"Haney","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"26316","DOI":"10.3402\/jev.v4.26316","article-title":"Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting","volume":"4","author":"Wiklander","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41467-018-03733-8","article-title":"Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson\u2019s disease treatment","volume":"9","author":"Kojima","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/mds.25978","article-title":"Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice","volume":"29","author":"Cooper","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"30371","DOI":"10.1016\/j.ymthe.2019.08.010","article-title":"Systemic exosomal delivery of shRNA minicircles prevents Parkinsonian pathology","volume":"27","author":"Izco","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"235","DOI":"10.6026\/97320630002235","article-title":"RNAi and RNAa--the yin and yang of RNAome","volume":"2","author":"Pushparaj","year":"2008","journal-title":"Bioinformation"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"956563","DOI":"10.3389\/fbioe.2022.956563","article-title":"Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer","volume":"10","author":"Dalmizrak","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12964-022-01017-9","article-title":"The potential use of mesenchymal stem cells-derived exosomes as microRNAs delivery systems in different diseases","volume":"21","author":"Oveili","year":"2023","journal-title":"Cell. Commun. Signal."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Vilaca-Faria, H., Salgado, A.J., and Teixeira, F.G. (2019). Mesenchymal stem cells- derived exosomes: A new possible therapeutic strategy for Parkinson\u2019s disease?. Cells, 8.","DOI":"10.3390\/cells8020118"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/stem.1129","article-title":"Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth","volume":"30","author":"Xin","year":"2012","journal-title":"Stem Cells"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.omtn.2021.01.022","article-title":"Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson\u2019s disease","volume":"23","author":"Li","year":"2021","journal-title":"Mol. Nucleic. Acids"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"107873","DOI":"10.1016\/j.pharmthera.2021.107873","article-title":"Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson\u2019s disease","volume":"227","author":"Bortolozzi","year":"2021","journal-title":"Pharm. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/elps.201700491","article-title":"Simultaneous Isolation and Preconcentration of Exosomes by Ion Concentration Polarization","volume":"39","author":"Marczak","year":"2018","journal-title":"Electrophoresis"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"13495","DOI":"10.1039\/C7NR04557C","article-title":"High-Purity Capture and Release of Circulating Exosomes Using an Exosome- Specific Dual-Patterned Immunofiltration (ExoDIF) Device","volume":"9","author":"Kang","year":"2017","journal-title":"Nanoscale"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"27441","DOI":"10.1021\/acsami.7b06464","article-title":"Chemically Edited Exosomes with Dual Ligand Purified by Microfluidic Device for Active Targeted Drug Delivery to Tumor Cells","volume":"9","author":"Wang","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1021\/acsnano.6b06131","article-title":"Exodisc for Rapid, Size-Selective, and Efficient Isolation and Analysis of Nanoscale Extracellular Vesicles from Biological Samples","volume":"11","author":"Woo","year":"2017","journal-title":"ACS Nano."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"10712","DOI":"10.1021\/acsnano.7b04878","article-title":"The Exosome Total Isolation Chip","volume":"11","author":"Liu","year":"2017","journal-title":"ACS Nano."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nnano.2016.134","article-title":"Nanoscale lateral displacement arrays for the separation of exosomes and colloids down to 20\u2005nm","volume":"11","author":"Wunsch","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41556-018-0040-4","article-title":"Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation","volume":"20","author":"Zhang","year":"2018","journal-title":"Nat. Cell. Biol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1021\/acsnano.7b08199","article-title":"Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood","volume":"12","author":"Lewis","year":"2018","journal-title":"ACS Nano."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/2472630319846877","article-title":"Advances in Technologies for Purification and Enrichment of Extracellular Vesicles","volume":"24","author":"Zhang","year":"2019","journal-title":"SLAS Technol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"E968","DOI":"10.1073\/pnas.1521230113","article-title":"Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes","volume":"113","author":"Kowal","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"31295","DOI":"10.3402\/jev.v5.31295","article-title":"Nanoparticle analysis sheds budding insights into genetic drivers of extracellular vesicle biogenesis","volume":"5","author":"Hurwitz","year":"2016","journal-title":"J. Extracell. Vesicles"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"18397","DOI":"10.3402\/jev.v1i0.18397","article-title":"Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation","volume":"1","author":"Bobrie","year":"2012","journal-title":"J. Extracell. Vesicles"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"115142","DOI":"10.1016\/j.bios.2023.115142","article-title":"Multi-marker profiling of extracellular vesicles using streaming current and sequential electrostatic labeling","volume":"227","author":"Sahu","year":"2023","journal-title":"Biosens. Bioelectron."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Seow","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.7150\/thno.30853","article-title":"Design strategies and application progress of therapeutic exosomes","volume":"9","author":"Liu","year":"2019","journal-title":"Theranostics"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jconrel.2016.09.016","article-title":"Good things come in small packages: Overcoming challenges to harness extracellular vesicles for therapeutic delivery","volume":"241","author":"Ingato","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"20083","DOI":"10.1074\/jbc.M301642200","article-title":"Exosome release is regulated by a calcium-dependent mechanism in K562 cells","volume":"278","author":"Savina","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/biosci\/biv084","article-title":"Extracellular vesicles: Composition, biological relevance, and methods of study","volume":"65","author":"Zaborowski","year":"2015","journal-title":"Bioscience"},{"key":"ref_156","first-page":"1659","article-title":"Myocardial reparative functions of exosomes from mesenchymal stem cells are enhanced by hypoxia treatment of the cells via transferring microRNA-210 in an nSMase2-dependent way","volume":"46","author":"Zhu","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e16899","DOI":"10.1371\/journal.pone.0016899","article-title":"Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia\/lymphoma T and B cells","volume":"6","author":"Hedlund","year":"2011","journal-title":"PLoS ONE"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/ijc.24479","article-title":"Lung cancer secreted microvesicles: Underappreciated modulators of microenvironment in expanding tumors","volume":"125","author":"Wysoczynski","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"34211","DOI":"10.1074\/jbc.M109.041152","article-title":"Microenvironmental pH is a key factor for exosome traffic in tumor cells","volume":"284","author":"Parolini","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1248\/bpb.b17-00919","article-title":"A novel strategy to increase the yield of exosomes (extracellular vesicles) for an expansion of basic research","volume":"41","author":"Emam","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1479-5876-9-47","article-title":"Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs","volume":"9","author":"Chen","year":"2011","journal-title":"J. Transl. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1522236","DOI":"10.1080\/20013078.2018.1522236","article-title":"Engineering mesenchymal stem cells to improve their exosome efficacy and yield for cell-free therapy","volume":"7","author":"Phan","year":"2018","journal-title":"J. Extracell. Vesicles"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40259-020-00434-x","article-title":"Designer exosomes: A new platform for biotechnology therapeutics","volume":"34","author":"Jafari","year":"2020","journal-title":"BioDrugs"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Wang, J., Bonacquisti, E.E., Brown, A.D., and Nguyen, J. (2020). Boosting the biogenesis and secretion of mesenchymal stem cell-derived exosomes. Cells, 9.","DOI":"10.1101\/2020.02.08.940122"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.2147\/IJN.S264498","article-title":"Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted Therapy Applications","volume":"15","author":"Zhang","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.atherosclerosis.2017.03.045","article-title":"High miR-124-3p expression identifies smoking individuals susceptible to atherosclerosis","volume":"263","author":"Kok","year":"2017","journal-title":"Atherosclerosis"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9547\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:45:58Z","timestamp":1760125558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/11\/9547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":166,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms24119547"],"URL":"https:\/\/doi.org\/10.3390\/ijms24119547","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]}}}